R&D channel feed

Grail’s blood test charts path for di­ag­nos­ing pa­tients sus­pect­ed of hav­ing can­cer in large study: #AS­CO23

3 years ago

No­var­tis’ Kisqali pre­vents breast can­cer from com­ing back for longer — but can it best Eli Lil­ly’s Verzenio? #AS­CO23

3 years ago

Green­Light Bio­sciences se­cures merg­er as it looks to go pri­vate

3 years ago
Manufacturing

FDA lifts hold on Mol­e­c­u­lar Tem­plates’ mul­ti­ple myelo­ma tri­al af­ter less than two months

3 years ago
FDA+

As­traZeneca gives up on late-stage IL-23 drug due to tri­al de­lays, com­pet­i­tive land­scape

3 years ago

FDA ap­proves As­traZeneca's Lyn­parza com­bo for adults with BR­CA-mu­tat­ed prostate can­cer

3 years ago

Pre­ci­sion Bio­Sciences to meet with FDA af­ter tout­ing al­lo­gene­ic CAR-T win

3 years ago
Cell/Gene Tx

Vi­o­let Ther­a­peu­tics snags $10.6M in seed fund­ing for plat­forms that go be­yond sin­gle-cell se­quenc­ing

3 years ago

Glyscend Ther­a­peu­tic­s' ear­ly da­ta show poly­mer mim­ics ben­e­fits of surgery in type 2 di­a­betes, obe­si­ty

3 years ago

Sanofi rolls out PhII mul­ti­ple scle­ro­sis da­ta that will take the phar­ma in­to piv­otal stud­ies next year

3 years ago
Pharma

Chi­na's mar­ket reg­u­la­tor fines, con­fis­cates rev­enue from phar­mas for mo­nop­o­liz­ing APIs for ep­i­neph­rine

3 years ago
China

Ake­bia to re­file ane­mia drug vadadu­s­tat af­ter FDA de­nied ap­peal

3 years ago

C4 Ther­a­peu­tics gets $35M from Bet­ta Phar­ma­ceu­ti­cals to de­vel­op and mar­ket NSCLC drug in Chi­na

3 years ago
Deals
China

Pfiz­er’s once-a-week he­mo­phil­ia an­ti­body re­duces bleed­ing in PhI­II study

3 years ago

Af­ter PhI­II let­down, Rain On­col­o­gy lays off 65% of staff, al­ters clin­i­cal plans for sole as­set

3 years ago
People

EU com­mit­tee like­ly to rec­om­mend against ap­prov­ing Amy­lyx ALS drug, com­pa­ny says

3 years ago
Pharma
FDA+

Ve­rastem touts mid-stage da­ta in rare type of ovar­i­an can­cer: #AS­CO23

3 years ago

With cash run­ning low, Swedish cell ther­a­py com­pa­ny looks to sell off plat­form

3 years ago
Cell/Gene Tx

Evax­ion teas­es 67% re­sponse rate in PhI metasta­t­ic melanoma tri­al

3 years ago

Take­da wins pri­or­i­ty re­view for $400M col­orec­tal can­cer drug, li­censed from Hutchmed in Jan­u­ary

3 years ago
FDA+

Arti­va boasts ear­ly NK cell ther­a­py re­sults, giv­ing life­line to part­ner Af­fimed

3 years ago

Out­pace Bio ex­pands cell ther­a­py R&D, nets re­search col­lab­o­ra­tions in Seat­tle

3 years ago
Cell/Gene Tx

As­traZeneca's Lyn­parza-Imfinzi com­bo hits pri­ma­ry end­point in PhI­II en­dome­tri­al can­cer tri­al DUO-E

3 years ago

Car­mot rais­es an­oth­er $150M for obe­si­ty drugs, though race by com­peti­tors is well un­der­way

3 years ago
Financing
Startups
First page Previous page 84858687888990 Next page Last page
A service from the Financial Times